Moreover, the identification of compounds with dual LSD1/EGFR inhibitory activity provides new insights into the development of more effective cancer treatments, particularly for cases where single-target therapies have shown limited efficacy or led to resistance. The gene discussed is KDM1A; the disease is cancer.